SAN DIEGO, April 19, 2018 – ProSciento, a full scope clinical R&D services provider focused exclusively on metabolic diseases, will present scientific data at the 2nd Annual NASH Summit in Boston, April 23-25, 2018. ProSciento’s Chief Medical Officer, Dr. Linda Morrow, will also present “Notes from the Field: Strategies for Successful NAFLD & NASH Trials” at the Summit’s morning plenary session on Wednesday, April 25.
The poster presentation, co-authored with OWL Metabolomics, is titled “Application of a Non-Invasive Integrated Screening Algorithm to Improve Enrollment in NAFLD/NASH Clinical Trials.” The poster summarizes data from an initial pre-screening program to investigate the utility of ProSciento’s non-invasive screening algorithm combined with OWL’s lipidomic testing panel to identify individuals with a high probability of eligibility for NAFLD/NASH clinical studies. The program included 204 individuals with type 2 diabetes and 178 obese, non-diabetic individuals. Results indicate that the integrated approach may be a scalable, efficient means to identify individuals with steatosis or steatohepatitis prior to MRI or biopsy and therefore reduce screen failure rates in enrollment phase of NAFLD/NASH clinical trials.
ProSciento’s Chief Executive Officer, Dr. Marcus Hompesch, and Chief Medical Officer, Dr. Linda Morrow, will both attend the Summit. To inquire about a meeting, please contact firstname.lastname@example.org.
About ProSciento, Inc.
ProSciento is a metabolism-focused, full scope clinical R&D services provider, with a mission to advance the global development of novel therapeutics for NASH, diabetes and obesity. The company is widely recognized for quality and scientific excellence, an unparalleled methodological toolkit, and extensive experience with virtually all metabolic drug and device classes. Utilizing its scalable R&D services model – combining deep therapeutic area expertise, strategic planning, an unparalleled methodological tool kit, and operational execution from late preclinical to phase III readiness – ProSciento provides highly customizable services for its global client base in today’s rapidly evolving landscape of metabolic drug and device development. For more information, please visit www.prosciento.com.
For media inquiries, please contact:
Senior Director, Corporate Communications, ProSciento, Inc.
Tel: +1 858 663-6148
For business development inquires:
For clinical study enrollment inquires:
Tel: +1 (866) 308-7427